Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral steroid-free induction therapy for lupus nephritis
2020-005835-60Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Steroid-free obinutuzumab + MMF regimen with Oral corticosteroid + MMF regimen (2 arms). Primary endpoint: Complete renal response at week 52 without excess corticosteroid exposure. Started May 2021; status: active.
02
Drugs
obinutuzumabmycophenolate mofetilprednisone
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2020-005835-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005835-60.